Serum immunoreactive pancreatic phospholipase A2 in patients with various malignant tumors.

Enzyme Pub Date : 1990-01-01 DOI:10.1159/000468710
Y Oka, M Ogawa, Y Matsuda, A Murata, J Nishijima, K Miyauchi, K Uda, T Yasuda, T Mori
{"title":"Serum immunoreactive pancreatic phospholipase A2 in patients with various malignant tumors.","authors":"Y Oka,&nbsp;M Ogawa,&nbsp;Y Matsuda,&nbsp;A Murata,&nbsp;J Nishijima,&nbsp;K Miyauchi,&nbsp;K Uda,&nbsp;T Yasuda,&nbsp;T Mori","doi":"10.1159/000468710","DOIUrl":null,"url":null,"abstract":"<p><p>The high incidence (40.6%) of elevated serum pancreatic phospholipase A2 (PLA2) was demonstrated in patients with various malignancies. Serum PLA2 was significantly increased in cancer patients compared with healthy sex- and age-matched blood donors (358.4 +/- 168.0 vs. 241.7 +/- 69.0 ng/dl; p less than 0.01). No correlation was observed between serum PLA2 and carcinoembryonic antigen (CEA) in these patients. Although patients with advanced and distantly metastatic cancer of the liver, gallbladder and pancreas showed higher PLA2 levels in serum than those with early cancer, patients with other cancers showed no correlation between serum PLA2 and clinical stage. A combined assay of PLA2 and CEA increased the sensitivity of detection of cancers to 60.8%.</p>","PeriodicalId":11933,"journal":{"name":"Enzyme","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000468710","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enzyme","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000468710","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 17

Abstract

The high incidence (40.6%) of elevated serum pancreatic phospholipase A2 (PLA2) was demonstrated in patients with various malignancies. Serum PLA2 was significantly increased in cancer patients compared with healthy sex- and age-matched blood donors (358.4 +/- 168.0 vs. 241.7 +/- 69.0 ng/dl; p less than 0.01). No correlation was observed between serum PLA2 and carcinoembryonic antigen (CEA) in these patients. Although patients with advanced and distantly metastatic cancer of the liver, gallbladder and pancreas showed higher PLA2 levels in serum than those with early cancer, patients with other cancers showed no correlation between serum PLA2 and clinical stage. A combined assay of PLA2 and CEA increased the sensitivity of detection of cancers to 60.8%.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
各种恶性肿瘤患者血清免疫反应性胰磷脂酶A2的变化。
血清胰磷脂酶A2 (PLA2)升高在各种恶性肿瘤患者中发生率高(40.6%)。与性别和年龄匹配的健康献血者相比,癌症患者血清PLA2显著升高(358.4 +/- 168.0对241.7 +/- 69.0 ng/dl;P < 0.01)。这些患者血清PLA2与癌胚抗原(CEA)无相关性。晚期及远处转移性肝癌、胆囊癌和胰腺癌患者血清PLA2水平高于早期癌症患者,而其他癌症患者血清PLA2水平与临床分期无相关性。PLA2和CEA联合检测将癌症检测的敏感性提高到60.8%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Functional hepatocellular heterogeneity for the production of plasma proteins. Liver cell heterogeneity: functions of non-parenchymal cells. Hepatocyte heterogeneity in the metabolism of carbohydrates. Zonal liver cell heterogeneity. Hepatocyte heterogeneity in the metabolism of amino acids and ammonia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1